panitumumab,cetuximab,bevacizumab
amgen,eli lilly,takeda,roche
['dance', 'paradigm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'fire-4']
interesting abstracts re: egfri on d3 #asco23: fire-4, paradigm, gozila, highlight ctdna a/w outcome 1. confirm greatest benefits of egfri for l sided kras/braf v600e wt mcrc 2. tissue-ctdna discordance exists. why 
Incoming GI oncologist at UW Fred Hutch Cancer Center. Graduating UPMC fellow. Trials/early phase/AI/ML. Views my own. ✈️🚵‍♀️🏔🏸⚾️🎥.